Methods and Compositions for the Treatment of Cns-Related Conditions
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,058,291 | Methods and Compositions for the Treatment of Cns-Related Conditions In force · Medium confidence UsedRemaining | Adamas Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 7,619,007 | Method and Composition for Administering an Nmda Receptor Antagonist to a Subject Term ended Ended no later than Nov 22, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Ended no later than Nov 22, 2025 | Medium confidence | |
| US 8,173,708 | Method and Composition for Administering an Nmda Receptor Antagonist to a Subject Term ended Term ended Nov 22, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Term ended Nov 22, 2025 | Medium confidence | |
| US 8,283,379 | Methods and Compositions for the Treatment of Cns-Related Conditions Term ended Term ended Nov 22, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Term ended Nov 22, 2025 | Medium confidence | |
| US 8,293,794 | Methods and Compositions for the Treatment of Cns-Related Conditions Term ended Term ended Nov 22, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Term ended Nov 22, 2025 | Medium confidence | |
| US 8,329,752 | Composition for Administering an Nmda Receptor Antagonist to a Subject Term ended Ended no later than Nov 22, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Ended no later than Nov 22, 2025 | Medium confidence | |
| US 8,338,485 | Compositions for the Treatment of Cns-Related Conditions Term ended Ended no later than Nov 22, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Ended no later than Nov 22, 2025 | Medium confidence | |
| US 8,338,486 | Methods for the Treatment of Cns-Related Conditions Term ended Ended no later than Nov 22, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Ended no later than Nov 22, 2025 | Medium confidence | |
| US 8,362,085 | Method for Administering an Nmda Receptor Antagonist to a Subject Term ended Ended no later than Nov 22, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Ended no later than Nov 22, 2025 | Medium confidence | |
| US 8,426,472 | Method and Composition for Administering an NMDA Receptor Antagonist to a Subject Term ended Term ended Nov 22, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Term ended Nov 22, 2025 | Medium confidence | |
| 23 more records in this group · Pro | ||||||
10 of 33 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 33, including 12 expired.
1 of these is in force and held by Adamas Pharmaceuticals, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.